ArticleAmerican journal of respiratory and critical care medicine2021

A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast!

Yongneng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.